The risks and costs of multiple-generic substitution of topiramate

Neurology

Volumn 72, Issue 24, 2009, Pages 2122-2129

  Duh, M S ^a   Paradis, P E ^b   Latremouille Viau D ^b   Greenberg, P E ^a   Lee, S P ^c   Durkin, M B ^d   Wan, G J ^d   Rupnow, M F T ^e   Lelorier, J ^f  

^a ANALYSIS GROUP   (United States)

^b GROUPE D ANALYSE   (Canada)

^c Johnson and Johnson Pharmaceutical Services   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e ETHICON INC   (United States)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; FOSINOPRIL; GABAPENTIN; GENERIC DRUG; ISOSORBIDE 5 NITRATE; LAMOTRIGINE; PRAVASTATIN; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE;

ADULT; ANGINA PECTORIS; ARTICLE; CANADA; DEPRESSION; DRUG SUBSTITUTION; DRUG USE; EPILEPSY; FEMALE; FRACTURE; HEAD INJURY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONEY; PRIORITY JOURNAL;

EID: 67649499946     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181aa5300     Document Type: Article

References (11)

1. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Safety 2000;23:173-182.
2. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-1592.
3. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to brand compounds compared to other drug classes. Epilepsia 2006;48:464-469.
4. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008;70:2179- 2186.
5. Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cre'mieux PY. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis Manage 2007;10:216- 225.
6. LeLorier J, Duh MS, Paradis PE, et al. Economic impact of generic substitution of lamotrigine: projected costs in the United States using findings in a Canadian setting. Curr Med Res Opin 2008;24:1069-1081.
7. National Conference of State Legislature, 2006 Prescription Drug State Legislation. Available at: http://www. ncsl.org/programs/health/drugbill06.htm. Accessed March 26, 2008.
8. National Conference of State Legislature, 2007 Prescription Drug State Legislation. Available at: http://www. ncsl.org/programs/health/drugbill07.htm. Accessed March 26, 2008.
9. National Conference of State Legislature, 2008 Prescription Drug State Legislation. Available at: http://www. ncsl.org/programs/health/drugbill08.htm. Accessed March 26, 2008.
10. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;34:187-220.
11. Sander JW. The use of antiepileptic drugs-principles and practice. Epilepsia 2004;45(suppl 6):28-34.